2 completed, 2 terminated. 3 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow TC99m-tilmanocept: new trials by email Literature Review of TC99m-tilmanocept trials Research Report on TC99m-tilmanocept
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA TC99m-tilmanocept - Rheumatoid Arthritis | Phase 3 | Terminated | Navidea Biopharmaceuticals | 169 | 2022-03-02 | 2025-01-23 |
| Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH Tc 99M Sulfur Colloid, Tc99m-tilmanocept - Nonalcoholic Steatohepatitis, NASH - Nonalcoholic Steatohepatitis | Phase 1 | Terminated | Navidea Biopharmaceuticals | 6 | 2017-12-06 | 2024-12-24 |
| An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS) Tc99m-tilmanocept - Kaposi Sarcoma, HIV Infections | Phase 1 | Completed | Navidea Biopharmaceuticals | 15 | 2017-12-01 | 2025-03-05 |
| Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA Tc99m-tilmanocept, SPECT Imaging (60 Minutes post-injection), SPECT Imaging (180 Minutes post-injection) - Arthritis, Rheumatoid | Phase 1 / Phase 2 | Completed | Navidea Biopharmaceuticals | 39 | 2017-01-01 | 2021-08-12 |
Arthritis, Rheumatoid (2) · HIV Infections (1) · Non-alcoholic Fatty Liver Disease (1) · Sarcoma, Kaposi (1)
Navidea Biopharmaceuticals (4)
United States (4)
Michael Blue, MD (3) · Micheal Blue, MD (1)
R44CA192859 (1)